Healthcare entity
All 1 tracked stories fall under one category: market-trends. Casdatifan is most often covered alongside ARC-20 Trial, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Casdatifan appears in 1 tracked Healthcare story from July 28, 2026.
Last mentioned: Jul 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Casdatifan is most often covered alongside ARC-20 Trial, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Casdatifan appears in 1 tracked Healthcare story from July 28, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Casdatifan. Shared-story counts are live from our verified record — not editorial picks.
A phase 1 trial of the oral HIF-2α inhibitor casdatifan in 127 heavily pretreated ccRCC patients demonstrated durable tumor responses and a manageable safety profile. The findings, published in Nature, may guide future biomarker-based treatment strategies, potentially reducing futile therapies and optimizing resource use in oncology care.
Casdatifan is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
